Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy

Klinik für Anästhesiologie

Overview

Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.

Study Type

OBSERVATIONAL

Conditions

Kidney Replacement Disorder

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy Exclusion Criteria: * Age \< 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study

Locations (1)

Interdisciplinary Operative Intensive Care Unit, University Hospital Duesseldorf

Düsseldorf, North Rhine-Westphalia, Germany

Outcomes

Primary Outcomes

Filter life time of continuous renal replacement therapy

Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.

Time frame: Individual time point, standardized

Secondary Outcomes

Activation of coagulation

blood samples for multiplate, rotem and systemic coagulation paramters

Time frame: beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.